Zacks: Analysts Expect Genprex, Inc. (NASDAQ:GNPX) Will Post Earnings of -$0.09 Per Share

Equities analysts expect Genprex, Inc. (NASDAQ:GNPXGet Rating) to report earnings of ($0.09) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Genprex’s earnings. Genprex posted earnings of ($0.14) per share during the same quarter last year, which would indicate a positive year over year growth rate of 35.7%. The business is scheduled to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Genprex will report full year earnings of ($0.42) per share for the current year. For the next year, analysts anticipate that the firm will post earnings of ($0.48) per share. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Genprex.

Genprex (NASDAQ:GNPXGet Rating) last posted its earnings results on Wednesday, March 30th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02).

Hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. raised its position in shares of Genprex by 443.1% in the first quarter. Goldman Sachs Group Inc. now owns 121,573 shares of the company’s stock worth $275,000 after buying an additional 99,186 shares in the last quarter. Virtu Financial LLC grew its stake in shares of Genprex by 198.6% in the fourth quarter. Virtu Financial LLC now owns 125,185 shares of the company’s stock worth $164,000 after purchasing an additional 83,263 shares during the last quarter. D. E. Shaw & Co. Inc. grew its stake in shares of Genprex by 46.0% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 125,234 shares of the company’s stock worth $164,000 after purchasing an additional 39,466 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Genprex by 92.6% in the second quarter. Bank of America Corp DE now owns 40,386 shares of the company’s stock worth $136,000 after purchasing an additional 19,414 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of Genprex in the first quarter worth about $68,000. Institutional investors own 15.66% of the company’s stock.

Shares of GNPX stock opened at $1.49 on Friday. Genprex has a 52-week low of $1.17 and a 52-week high of $4.07. The company has a market capitalization of $71.37 million, a PE ratio of -3.47 and a beta of -0.50. The business’s fifty day moving average is $1.74 and its 200 day moving average is $1.87.

About Genprex (Get Rating)

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes.

See Also

Get a free copy of the Zacks research report on Genprex (GNPX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.